Halozyme, Inc.

The Scripps Research Institute

Biomarin Pharmaceutical Inc.

Qualcomm Incorporated

Lin Wang

H Michael Shepard

Christopher D Thanos

Suresh Kumar Venkumahanti

Raymond C Stevens

Paul Andrew Fitzpatrick

Daniel I Oppenheimer

Stephen Robert Shannon

Emilio Kakkis

Robert Heft

Alejandra Gamez

Woomi Kim

Mary Straub

Marianne Patch

Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.

Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

The present invention pertains to the use of the protein phenylalanine ammonia-lyase, as well as the biologically-active derivatives of the said protein for preventing or treating diseases associated with a phenylalanine imbalance in a human or animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating a phenylalanine imbalance in vivo. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting more therapeutically-effective variants of said protein as well as to the selected variants themselves.

Variants and chemically-modified variants of phenylalanine ammonia-lyase

Growing community of inventors

San Diego, CA, United States of America

Lin Wang